List of Figures
Figure 1: US Life Expectancy by Sex, 1950–2017 6
Figure 2: FDA Approvals, 1993–2018 8
Figure 3: Average Cost of Developing a Novel Drug ($m), 1970–2016 9
Figure 4: Projected R&D Returns (%), 2010-2017 10
Figure 5: Drivers of Shortened Pharmaceutical Product Life Cycles, 1970–2011 11
Figure 6: Patent Challenges by Generic Companies 12
Figure 7: FDA Approvals by Innovation Status, 1987–2017 13
Figure 8: Average Sales of First-in-Class and Non-First-in-Class Products After Launch ($m), 2006–2014 14
Figure 9: Average Projected Sales of First-in-Class and Non-First-in-Class Products Launched in 2015 ($m), 2016–2022 14
Figure 10: FDA Orphan Drug Approvals, 1983–2017 15
Figure 11: Pipeline Products by Stage and Molecule Type, Q3 2018 17
Figure 12: Pipeline Products by Therapy Area, Q3 2018 18
Figure 13: Overall Pipeline, Number of Products and Pipeline Growth by Therapy Area, Q1 2015–Q3 2018 19
Figure 14: Number of Clinical Trials Initiated, 2007–2017 21
Figure 15: Number of Clinical Trials Initiated by Therapy Area, 2007–2017 22
Figure 16: Pipeline Products by Therapy Area and Stage of Development (%), Q3 2018 24
Figure 17: Pipeline Products by Therapy Area and Stage of Development, Q3 2018 25
Figure 18: Pipeline Products by Therapy Area and Molecule Type, Q3 2018 27
Figure 19: Pipeline Products by Therapy Area and Molecule Type, Q3 2018 28
Figure 20: Oncology Pipeline Products by Indication, Q3 2018 30
Figure 21: Oncology Pipeline, Number of Products by Indication, Q1 2015–Q3 2018 31
Figure 22: Infectious Disease Pipeline, Number of Products by Indication, Q3 2018 32
Figure 23: Infectious Disease Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015–Q3 2018 33
Figure 24: Central Nervous System Pipeline, Number of Products by Indication, Q3 2018 34
Figure 25: Central Nervous System Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015–Q3 2018 35
Figure 26: Immunology Pipeline, Number of Products by Indication, Q3 2018 36
Figure 27: Immunology Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015–Q3 2018 37
Figure 28: Pipeline Products by Therapy Area and Proportion of Established and First-in-Class Products, Q3 2018 39
Figure 29: First-in-Class Pipeline, Number of Products and Pipeline Growth by Therapy Area, Q1 2015–Q3 2018 40
Figure 30: First-in-class Pipeline Products by Therapy Area and Stage of Development, Q3 2018 42
Figure 31: First-in-Class Oncology Pipeline Products by Indication, Q3 2018 43
Figure 32: First-in-Class Oncology Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015–Q3 2018 44
Figure 33: First-in-Class Infectious-Diseases Pipeline Products by Indication, Q3 2018 46
Figure 34: First-in-Class Infectious Disease Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015–Q3 2018 47
Figure 35: First-in-Class Central Nervous System Disorder Pipeline Products by Indication, Q3 2018 49
Figure 36: First-in-Class Central Nervous System Disorder Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015–Q3 2018 50
Figure 37: First-in-Class Immunology Disorder Pipeline, Number of Products by Indication, Q3 2018 52
Figure 38: First-in-Class Immunology Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015–Q3 2018 53